Biogen (BUE:BIIB) Accounts Payable

: ARS97,037 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's Accounts Payable for the quarter that ended in Mar. 2023 was ARS97,037 Mil.

Biogen's quarterly Accounts Payable increased from Sep. 2022 (ARS53,246 Mil) to Dec. 2022 (ARS82,400 Mil) and increased from Dec. 2022 (ARS82,400 Mil) to Mar. 2023 (ARS97,037 Mil).

Biogen's annual Accounts Payable increased from Dec. 2020 (ARS37,020 Mil) to Dec. 2021 (ARS59,503 Mil) and increased from Dec. 2021 (ARS59,503 Mil) to Dec. 2022 (ARS82,400 Mil).

Biogen Accounts Payable Historical Data

The historical data trend for Biogen's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable

13,969.70

31,727.83

37,019.76

59,503.31

82,399.97

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Accounts Payable																42,809.24	52,319.49	53,245.64	82,399.97	97,036.56

Biogen Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Biogen Accounts Payable Related Terms

Thank you for viewing the detailed overview of Biogen's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.